Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis

Cairo University (CU) logo

Cairo University (CU)

Status and phase

Completed
Phase 2
Phase 1

Conditions

Systemic Lupus Erythematosis

Treatments

Drug: Hydroxychloroquine
Drug: Hydrocortisone
Drug: Cyclophosphamide

Study type

Interventional

Funder types

Other

Identifiers

NCT02756546
BC (1016)

Details and patient eligibility

About

This study aims to identify the expression signature of miR-181a, miR-196a and miR-21 in plasma of SLE patients and difference in their expression among groups with different systemic lupus erythematosis disease activity index (SLEDAI) scores.

Enrollment

100 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Adult systemic lupus erythematosis patients

Exclusion criteria

Patients younger than 18 years, patients with other autoimmune diseases or malignancy.

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

100 participants in 2 patient groups

Control
No Intervention group
Description:
Healthy volunteers
Patients
Active Comparator group
Description:
SLE patients further divided into mild and severe patients
Treatment:
Drug: Cyclophosphamide
Drug: Hydrocortisone
Drug: Hydroxychloroquine

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems